Current Issue : January - March Volume : 2017 Issue Number : 1 Articles : 6 Articles
Background and Aim. Contact dermatitis (CD) is the most prevalent occupational skin disease with a significant impact on quality\nof life. Patch testing is used for the identification of responsible allergens which may improve protective and preventive measures\nin the workplace. Herein, we aim to identify the demographic characteristics and occupation of patients with early diagnosis of\noccupational CD and compare patch test results. Materials and Methods. The study included 330 patients referred to our clinic\nbetween April 2009 and April 2011 and who were patch-tested with 28-allergen European Standard Test. Results. 126 (38%) patients\nwere female and 204 (62%) were male with amean age of 36.12 (�±13.13) years. Positive allergic reactions were observed in 182 (55%)\npatients. Nickel sulphate (41/126) and potassium dichromate (39/204) were significantly the most common allergens in women\nand men, respectively (...
The role of cutaneous human papillomavirus (HPV) infection in the development of subsequent cutaneous squamous cell\ncarcinoma (SCC) is unknown. Pathologically confirmed cases of SCC (...
Background: Vitiligo is a common autoimmune inflammatory skin disease, where there are different\nsurgical techniques for treatment of stable patches of vitiligo. Objective: To find non-costly,\nminimally invasive, simple technique by direct melanocytes transplant by spade needle technique\nin treatment of vitiligo. Patients and Methods: This interventional, therapeutic, comparative study\nwas done in Department of Dermatology, Baghdad Teaching Hospital, Baghdad, Iraq from April\n2014-March 2015. Twenty patients with localized, generalized and segmental vitiligo were included.\nFull history and examination for each patient was done with 4 (20%) males and 16 (80%)\nfemales and their ages ranged from 9 - 40 (23.15 �± 11.44) years. Forty one patches in 20 patients\ntreated by spade grafting technique and the donor and recipient sites were demarcated and anesthesia\ndone by xylocaine 2% with adrenalin 1:100,000. Transplantation was started by using disposable\nneedle gauge 18 (the sharp end of needle was cut by a scissor to make it a spade like) with\nmedical syringe 5 ml supplied with normal saline. The micro-pieces were taken from donor site\nand transplanted directly, easily and rapidly into dermis of recipient site and followed by pushing\nnormal saline and the procedure was repeated to cover all recipient sites with 5 mm distance between\ninjection points. The surface area of the lesions was calculated and the reduction rate was\nestimated every month till the end of the 4th month period of the treatment. Results: Including 41\npatches in 20 patients with the surface area of the patches ranged from 1.5 - 90 cm2 (13.78 �±17.57) cm2. The mean �±SD of surface area of lesions was decreased from 13.78 �± 17.57 cm2 at\nbaseline visit to 13.61 �± 17.48 cm2 at the second visit (after 2 weeks ) which was statistically significant\n(p value 0.001). The mean surface area continued to be reduced till reaching 12.20 �±\n15.68 cm2 at the third visit and 12.01 �± 15.55 cm2 at the fourth visit. All were statistically significant\nwhen compared to baseline visit. There was reduction in surface area 1.1% at two weeks,\n9.93%, and 12.5% at the 2nd, 4th months respectively. Conclusions: Intradermal injection of melanocytes\nin patients with vitiligo by spade like needle was very quick and simple non-costly technique,\nand gave 12.5% reduction which could be repeated at different times until satisfactory\nre-pigmentation of vitiligenous skin is achieved....
Background: Autoimmune diseases like pemphigus and systemic lupus erythematosus are protective\nagainst skin malignancies like basal cell carcinoma and squamous cell carcinoma. Objective:\nAs vitiligo is an autoimmune diseases, the aim of the present work is to record the frequency of all\nbenign and malignant skin tumors among patients with different severity of vitiligo and to be\ncompared with the skin tumors in healthy control. Patients and Methods: This is a case series, descriptive\nstudy done in the Department of Dermatologyââ?¬â?Baghdad Teaching Hospital, Baghdad,\nIraq, during the period from May 2014-May 2015. History was taken from each patient with vitiligo\nregarding age, gender, duration, personal and family history of vitiligo and other autoimmune\ndiseases such as diabetes mellitus, thyroid dysfunction, and alopecia areata. Patients were assessed\nfor past and present history of photodermatosis and any skin cancers. Healthy control was\nconsidered. Results: Three hundred and fifty patients with vitiligo were included in this study: 50\npatients with universal vitiligo, 100 patients with generalized vitiligo, and 200 patients with localized\nvitiligo as well as 500 subjects as a healthy control. The ages of all studied subjects ranged\nbetween 31 and 77 years. Twenty four(48%) patients with universal vitiligo were males and 26\n(52%) were females; 49(49%) patients with generalized vitiligo were males and 51(51%) were\nfemales; 101(50.5%) patients with localized vitiligo were males and 99(49.5%) were females and\n235(47%) of control were males and 265(53%) were females. All skin tumors were seen to be\nhigh in healthy subjects and lower or absent in patients with vitiligo. Also patients with mild vitiligo\nhad a higher frequency of skin tumors including benign and malignant than patients with severe\nvitiligo especially in patients with universal vitiligo. In addition, no photosensitivity or actinic\nreticuloid was detected in patients with vitiligo. Conclusions: Vitiligo especially generalized and\nuniversal type as an autoimmune disease had a protective action against photodamage, photosen-sitivity and skin tumors whether benign or malignant....
Background: Keloid is a benign fibrous growth, which presents in scar tissue of predisposed individuals. It is a result of\nirregular wound healing, but the exact mechanism is unknown. However, several factors may play a role in keloid\nformation. To date, there are no studies of keloids in Syria, and limited studies on Caucasians, so we have investigated\nthe risk factors of keloids in Syrians (Caucasians), and this is the main objective of this study.\nMethods: Diagnosis of keloids was clinically made after an interview and physical examination. We did a histopathological\nstudy in case the physical examination was unclear.\nThe following information was taken for each patient; sex, Blood groups (ABO\\Rh), cause of scarring, anatomical\nsites, age of onset, number of injured sites (single\\multiple) and family history.\nResults: We have studied the clinical characteristics of 259 patients with keloids,130 (50.2 %) females and 129 (49.8 %)\nmales. There were 209 (80.7 %) patients with keloids in a single anatomical site compared to 50 (19.3 %) patients with\n130 keloids in multiple anatomical sites, 253 (97.68 %) patients with keloids caused by a single cause for each patient\ncompared to 6 (2.32 %) patients with keloids caused by two different causes for each patient.\nKeloids could follow any form of skin injury, but burn was the most common (28.68 %). Also, keloids could develop at\nany anatomical sites, but upper limb (20 %) followed by sternum (19.17 %) was the most common. Over half\nof the patients developed keloids in the 11ââ?¬â??30 age range. 19.3 % (50/259) of patients had family history, 76 % (38/50)\nof them had keloids located in the same anatomical sites of relative, also, 66 % (33\\50) of them had keloids caused by\nthe same cause.\nThe following information was found to be statistically significant; people with blood group A (p = 0.01) compared\nwith other blood groups, spontaneous keloids in patients with blood group A (p = 0.01), acne in males (p = 0.0008)\ncompared to females, acne in someone who has a previous acne keloid (p = 0.0002), burn in someone who has a\nprevious burn keloid (p = 0.029), family history, especially for spontaneous (p = 0.005), presternal (p = 0.039) and\nshoulder (p = 0.008) keloids, people in second and third decades (p = 0.02) (p = 0.01) respectively.\nConclusion: Age of onset, sex, cause of scarring, blood groups, anatomical site, presence of family history and\nthe number of site (multiple\\single) were significant in keloid formation in Syrians....
Background: Most psoriasis patients have mild to moderate disease, commonly treated topically. Current topical\nagents have limited efficacy and undesirable side effects associated with long-term use. Tofacitinib is a small\nmolecule Janus kinase inhibitor investigated for the topical treatment of psoriasis.\nMethods: This was a 12-week, randomized, double-blind, parallel-group, vehicle-controlled Phase 2b study of\ntofacitinib ointment (2 % and 1 %) applied once (QD) or twice (BID) daily in adults with mild to moderate plaque\npsoriasis. Primary endpoint: proportion of patients with Calculated Physician�s Global Assessment (PGA-C) clear or\nalmost clear and �2 grade improvement from baseline at Weeks 8 and 12. Secondary endpoints: proportion of\npatients with PGA-C clear or almost clear; proportion achieving Psoriasis Area and Severity Index 75 (PASI75)\nresponse; percent change from baseline in PASI and body surface area; change from baseline in Itch Severity Item\n(ISI). Adverse events (AEs) were monitored and clinical laboratory parameters measured.\nResults: Overall, 435 patients were randomized and 430 patients received treatment. The proportion of patients\nwith PGA-C clear or almost clear and �2 grade improvement from baseline at Week 8 was 18.6 % for 2 %\ntofacitinib QD (80 % confidence interval [CI] for difference from vehicle: 3.8, 18.2 %) and 22.5 % for 2 % tofacitinib\nBID (80 % CI: 3.1, 18.5 %); this was significantly higher vs vehicle for both dosage regimens. No significant difference\nvs vehicle was seen at Week 12. Significantly more patients achieved PGA-C clear or almost clear with 2 %\ntofacitinib QD and BID and 1 % tofacitinib QD (not BID) at Week 8, and with 2 % tofacitinib BID at Week 12. Pruritus\nwas significantly reduced vs vehicle with 2 % and 1 % tofacitinib BID (starting Day 2), and 2 % tofacitinib QD (starting\nDay 3). Overall, 44.2 % of patients experienced AEs, 8.1 % experienced application site AEs, and 2.3 % experienced\nserious AEs. The highest incidence of AEs (including application site AEs) was in the vehicle QD group.\nConclusions: In adults with mild to moderate plaque psoriasis, 2 % tofacitinib ointment QD and BID showed greater\nefficacy than vehicle at Week 8, but not Week 12, with an acceptable safety and local tolerability profile....
Loading....